Eris Lifesciences Ltd is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model. Ranked #21 in the IPM, Eris has established a leading presence in its core cardio-metabolic franchise in just 15 years from inception.
Eris is also successfully diversifying its business with 3 emerging therapies (Dermatology, Neuropsychiatry and Gynaecology) accounting for 20% of its revenue and growing at > 25% p.a.
We began our journey 15 years ago in 2007 with the vision to make a meaningful impact in the management of chronic lifestyle related diseases. Today Chronic and Sub-chronic therapies account for ~ 90% of our revenue, and our product range spans ~ 90% of India’s Rs. 55,000+ crore chronic care market.